US pharma bets big on China to snap up potential blockbuster drugs

U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CFk64zZ
via IFTTT